No State Subsidy for Two Cholesterol Pills After Their Maker Balks at Infarmed's Price, While a New Ovarian Cancer Drug Wins SNS Funding
Infarmed refused a co-payment for Nilemdo and Nustendi and kept the rare-disease drug Evkeeza out of hospitals over price, but approved Elahere after a deal.